earnings
confidence high
sentiment positive
materiality 0.75
Vertex Q1 product revenue $2.10B (+22% YoY); reiterates FY 2022 guidance $8.4-8.6B
VERTEX PHARMACEUTICALS INC / MA
2022-Q1 EPS reported
$2.96
revenue$2,097,500,000
- Product revenues $2.10B (+22% YoY); TRIKAFTA $1.76B (+48% YoY).
- GAAP diluted EPS $2.96; Non-GAAP diluted EPS $3.52 (up 18% YoY).
- Reaffirmed FY 2022 product revenue guidance $8.4-8.6B.
- Pipeline spans 6 disease areas; positive Phase 2 proof-of-concept studies; more therapies entering clinic H2 2022.
- Changed non-GAAP methodology; no longer exclude certain R&D milestone payments; recast prior periods.